2017年6月16日

2007年6月12日,11:27am ATHERSYS提出6500万美元的并发反向收购和私人股本OFFERINGCleveland€”ATHERSYS, Inc .,私营生物技术公司已经宣布,它已经成功地完成了一个反向合并BTHC VI, Inc . BTHC更名为ATHERSYS计划,公司一旦实际毕竟能满足应用需求。与合并,BTHC完成私人配售,导致总收入为6500万美元。并购交易完成后的全资子公司的合并BTHC Athersys,剩下Athersys作为存续公司和BTHC的全资子公司。由于合并,Athersys构成BTHCa€™s唯一的业务。Athersys已经取代了所有的官员和董事BTHC的官员和董事,该公司将保留所有Athersys员工和公司将保持其主要业务在克利夫兰,俄亥俄州。作为交易的一部分,BTHC出售了1300万股普通股每股5.00美元的机构和其他合格投资者。该公司还发布了权证的投资者购买额外普通股股价与每股6.00美元的价格。考恩和公司、有限责任公司和国家证券公司担任co-placement私人配售代理。半径企业融资,为其重要的合作伙伴OrbiMed Advisors RA Capital Management,猛禽Capital Management LLC Hambrecht &林鸽Capital Management LLC MPM BioEquities,和帕帕斯企业以及其他一些知名医疗机构投资者。加入董事会事务将被关闭的乔丹·戴维斯的管理合伙人半径,Mike Sheffery OrbiMed普通合伙人,和弗洛伊德d环,医学博士合资企业合伙人半径。所得资金将主要用于基金的持续临床开发Athersysa€™肥胖计划,包括它的领先候选人,athx - 105及其non-embryonic干细胞产品,MultiStemA®,为某些心血管疾病治疗病人,骨髓移植的支持,和其他疾病的迹象,一些临床前开发活动,偿债、营运资金和一般企业用途。一个€œWe投资Athersys感到兴奋与上市作为上市公司,一个€乔丹·戴维斯说。 “In particular, we are attracted to Athersys' “fast follower” approach and its focus on developing products that have “best-in-class” potential in multibillion dollar markets.”The securities issued by BTHC have not been registered under the Securities Act of 1933 or any state securities laws. Therefore, such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933 and any applicable state securities laws. This press release does not constitute an offer to purchase any securities or a solicitation of an offer to sell any securities.About AthersysAthersys is a biopharmaceutical and regenerative medicine company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of its proprietary technologies, it has established a pipeline of therapeutic product development programs in multiple disease areas. Athersys’ lead product candidate, ATHX-105, a highly selective agonist of the serotonin receptor 5HT2c, a validated molecular target located in the region of the brain that regulates appetite and food intake. Compounds acting on this target have been shown to reduce appetite and result in weight loss in animal models and humans. In addition to its lead product candidate, the company is developing novel pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary capabilities and technologies including Random Activation of Gene Expression (RAGE).Athersys is developing MultiStem® to treat patients for certain cardiovascular disorders, stroke, bone marrow transplantation and oncology support, as well as other disease indications. MultiStem is a patented stem cell product that is based on a special class of adult-derived stem cells known as Multi-Potent Adult Progenitor Cells (MAPC). MultiStem may be isolated from the bone marrow and other non-embryonic tissue sources, can be routinely expanded to create large product inventories, and is being developed for off-the-shelf treatment of patients. Athersys is a founding member of the Center for Stem Cell and Regenerative Medicine based in Cleveland, Ohio, with the Cleveland Clinic, University Hospitals and Case Western Reserve University. Read more on